Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03982459 | National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC | completed | N/A | 76 | University of California, San FranciscoOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 |
| clinicaltrials |
| NCT05146219 | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | completed | Phase 2 | 29 | TYK Medicines, IncINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT06747026 | Real-World Immuno-Radiotherapy for Advanced NSCLC(OCEANUS) | completed | — | 338 | Fengming KongOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01463423 | Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | completed | N/A | 256 | Stanford UniversityOTHER | 3 | Dec 19, 2024 | clinicaltrials |
| NCT06737367 | Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors(Stage I NSCLC) | completed | — | 800 | Jinling Hospital, ChinaOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT01789099 | A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.(UV1-hTERT2012L) | completed | Phase 1 / Phase 2 | 18 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT02754882 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 763 | Samsung Bioepis Co., Ltd.INDUSTRY | 13 | Dec 16, 2024 | clinicaltrials |
| NCT03518554 | A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05462795 | Liquid Biopsy for Early Non-small Lung Cancer Detection | completed | — | 171 | University of ArizonaOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735781 | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France | completed | — | 101 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05926180 | Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) | completed | Phase 1 | 25 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT00478699 | Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)(GECP-SCAT) | completed | Phase 3 | 500 | Spanish Lung Cancer GroupOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04946019 | MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT02175017 | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 104 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer(ARC-4) | completed | Phase 1 | 77 | Arcus Biosciences, Inc.INDUSTRY | 4 | Dec 9, 2024 | clinicaltrials |
| NCT06557967 | Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment | completed | — | 22,517 | Daiichi SankyoINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04238130 | Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection(EVOLUTION) | completed | — | 132 | Sun Yat-sen UniversityOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03995875 | Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC(AYAME) | completed | — | 529 | AstraZenecaINDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04691388 | A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor | completed | Phase 2 | 29 | Zhejiang Cancer HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03081689 | Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients | completed | Phase 2 | 46 | Spanish Lung Cancer GroupOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04629300 | Supportive Care Mobile Application for Patients With NSCLC | completed | N/A | 120 | Massachusetts General HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02135679 | The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy | completed | — | 204 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02613507 | Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer(CheckMate 078) | completed | Phase 3 | 504 | Bristol-Myers SquibbINDUSTRY | 4 | Nov 19, 2024 | clinicaltrials |
| NCT02113813 | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 1 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05807893 | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases(SUPER BRAIN) | completed | Phase 2 / Phase 3 | 40 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02488850 | Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC(HAMLET) | completed | N/A | 32 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05898763 | TEIPP Immunotherapy in Patients With NSCLC(TEIPP) | completed | Phase 1 / Phase 2 | 26 | Erasmus Medical CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02094261 | Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours(AURA2) | completed | Phase 2 | 210 | AstraZenecaINDUSTRY | 8 | Nov 6, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT04702607 | Functional Lung Imaging With DECT and 4DCT | completed | — | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05347797 | Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit | completed | N/A | 495 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05348187 | Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit | completed | N/A | 309 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05360225 | Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit | completed | — | 5,000 | QIAGEN Gaithersburg, IncINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05304793 | Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer | completed | N/A | 46 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03594747 | A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | completed | Phase 3 | 360 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT01725165 | Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 2 | Oct 24, 2024 | clinicaltrials |
| NCT03486730 | BT1718 in Patients with Advanced Solid Tumours. | completed | Phase 1 / Phase 2 | 72 | Cancer Research UKOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT03217071 | Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | completed | Phase 2 | 12 | Sue YomOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03293680 | Pembrolizumab in Elderly Patients With Advanced Lung Cancer | completed | Phase 2 | 83 | Spanish Lung Cancer GroupOTHER | 1 | Oct 23, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jan 9, 2025source: clinicaltrials